The Abilify Compulsive Behavior Problem
Abilify is one of the most prescribed antipsychotic medications in the world, used to treat schizophrenia, bipolar disorder, major depression, and other conditions. A dopamine partial agonist, it works by modulating dopamine activity in the brain. This same mechanism, researchers discovered, can trigger compulsive behaviors -- particularly gambling disorder, hypersexuality, compulsive eating, and compulsive shopping -- in some patients.
The FDA issued a drug safety communication in 2016 requiring new warnings about compulsive behavior risks. The warning came years after patients and families had reported devastating financial and personal consequences from gambling losses, sexual behavior, and other compulsive actions they could not control while taking Abilify. Many patients did not connect their behavior to the medication for years.
The 2019 Settlement
BMS and Otsuka reached a major settlement with the DOJ and private plaintiffs in 2019 resolving both criminal and civil claims. The civil settlement addressed the manufacturers' alleged failure to adequately warn prescribers and patients about compulsive behavior risks. Tens of thousands of individual patients received compensation through the settlement trust.
Settlement amounts varied based on the severity and duration of compulsive behavior, documented financial losses (particularly gambling losses), and the strength of individual causation evidence. Some patients who suffered catastrophic financial consequences from gambling received substantial individual settlements.
Are New Claims Still Viable?
The 2019 settlement resolved the primary MDL litigation. New claims for patients who were not part of the settlement and who discovered their injuries after the settlement period may still be viable, subject to applicable statutes of limitations and whether they can establish a causal connection between Abilify use and compulsive behavior. Consult a pharmaceutical injury attorney for a current case evaluation.
Who Might Still Have Claims
Patients who: took Abilify (aripiprazole), developed pathological gambling, hypersexuality, or other impulse control disorders while on the medication, and suffered financial or personal harm -- and who were not part of the 2019 settlement -- may still have claims. Document Abilify prescription records and evidence of the compulsive behavior and its financial or personal impact.
Status 2026
The primary Abilify MDL settlement is distributed. Individual claims outside the settlement timeline continue to be evaluated. Consult a pharmaceutical injury attorney about current claim viability.
How to Get Legal Help
If you believe you qualify based on the eligibility criteria described above, the next step is a free consultation with an experienced attorney. Most plaintiff-side attorneys handling these cases work on contingency -- meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation including receipts, correspondence, or evidence of the harm you experienced. Related: Repatha Lawsuit.
To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to LawsuitWatch alerts. Coverage is updated as new court filings, settlement announcements, and eligibility changes are made public.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Abilify Lawsuit: Compulsive Behavior Side Effects & Settlement: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Did Abilify cause gambling addiction?
Yes. The FDA issued a warning in 2016 about compulsive gambling and other impulse control disorders as side effects of aripiprazole (Abilify). Many patients experienced gambling disorder before this connection was recognized.
Did BMS settle the Abilify lawsuit?
Yes. BMS and Otsuka reached a major settlement in 2019 for over $700 million resolving MDL claims. The settlement has been distributed.
Can I still file an Abilify lawsuit?
If you were not part of the 2019 settlement and recently discovered the Abilify-compulsive behavior connection, consult a pharmaceutical injury attorney about current claim viability and limitations periods.
How much did Abilify patients receive?
Settlement amounts varied widely. Patients with catastrophic gambling losses and strong causal evidence received the largest individual settlements.
What other compulsive behaviors does Abilify cause?
Beyond gambling, the FDA warning covers compulsive sexual behavior, compulsive eating, compulsive shopping, and other impulse control disorders.